Patent 10100097 was granted and assigned to Zealand Pharma A/S on October, 2018 by the United States Patent and Trademark Office.
The present invention relates to truncated GIP analogs which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.